Resources from the same session
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors
Presenter: Toshio Shimizu
Session: Developmental therapeutics
Resources:
Abstract
Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
Presenter: Valerie Heong
Session: Developmental therapeutics
Resources:
Abstract
Presentation
Webcast
Invited discussant abstracts 127O and 128O
Presenter: Christian Dittrich
Session: Developmental therapeutics
Resources:
Presentation
Webcast
Geographic variations in PK and drug toxicity
Presenter: Alex A. Adjei
Session: Developmental therapeutics
Resources:
Presentation
Webcast
First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
Presenter: Sophie Postel-Vinay
Session: Developmental therapeutics
Resources:
Abstract
Presentation
Webcast
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Presenter: Byoung Chul Cho
Session: Developmental therapeutics
Resources:
Abstract
A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors
Presenter: Athanasios Pallis
Session: Developmental therapeutics
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.